Retatrutide is the most effective weight-loss drug ever tested in a Phase 3 trial. Eli Lilly reported positive topline results from the TRIUMPH-1 trial on May 21 evaluating retatrutide, a first-in-class once-weekly injectable GIP/GLP-1/glucagon triple hormone receptor agonist, in adults with obesity or overweight. At the 12 mg dose, participants lost an average of 70.3 pounds (28.3%) over 80 weeks. In an extension cohort of patients with BMI of 35 or above, weight loss reached 85.0 pounds (30.3%) at 104 weeks—patients continued losing weight beyond the initial treatment period. 45.3% of participants on the 12 mg dose achieved 30% or greater weight loss, a level long associated with bariatric surgery outcomes. Lilly’s Kenneth Custer said retatrutide “delivered a level of weight loss long associated with bariatric surgery.” Truist analysts wrote that the data “set a new benchmark for anti-obesity medications” and projected conservative worldwide peak sales of $12 billion to $19 billion. BMO anticipates a 2027 launch. GlobalData forecasts $15.6 billion in 2031 sales. Seven more TRIUMPH Phase 3 readouts are expected in 2026, including trials in type 2 diabetes and established cardiovascular disease.
Top Story: Retatrutide Delivers 28.3% Weight Loss in Phase 3
What Happened: Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-1 trial evaluating retatrutide in adults with obesity or overweight with at least one weight-related condition.
The Data: A New Benchmark
The TRIUMPH-1 results across all three doses demonstrated a dose-dependent weight-loss response that exceeds anything previously reported in a Phase 3 obesity trial:
12 mg dose (80 weeks): Mean weight loss of 70.3 pounds (28.3%). 45.3% of participants achieved 30% or greater weight loss.
9 mg dose (80 weeks): Mean weight loss of 64.4 pounds (25.9%).
4 mg dose (80 weeks): Mean weight loss of 47.2 pounds (19.0%). Lower discontinuation rate due to adverse events versus placebo.
Extension cohort (BMI of 35 or above, 12 mg dose, 104 weeks): Mean weight loss of 85.0 pounds (30.3%). Patients continued losing weight beyond the initial 80-week period.
Improvements were observed in cardiovascular risk factors including waist circumference, cholesterol, and blood pressure.
Why the Triple Mechanism Produces More Weight Loss
Retatrutide is a first-in-class triple hormone receptor agonist that simultaneously activates three metabolic pathways: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. Current approved obesity drugs target one or two of these pathways. Wegovy targets GLP-1 alone. Zepbound targets GIP and GLP-1 together. Retatrutide adds glucagon receptor agonism as a third mechanism.
The glucagon component appears to be the differentiator. Glucagon increases energy expenditure and promotes fat oxidation—the body burning stored fat for energy—through mechanisms that are independent of appetite suppression. GLP-1 and GIP primarily reduce food intake by suppressing appetite and slowing gastric emptying. Adding glucagon on top of those appetite effects creates a dual approach: patients eat less (GLP-1/GIP) and burn more of what they have stored (glucagon). The result is 28.3% weight loss at 80 weeks versus approximately 22% for the dual agonist Zepbound and approximately 15% for the single agonist Wegovy.
The Bariatric Surgery Comparison
The 30% or greater weight loss threshold is significant because it has historically been achievable only through bariatric surgery. Sleeve gastrectomy typically produces 25-30% weight loss. Roux-en-Y gastric bypass typically produces 30-35%. Retatrutide at the 12 mg dose produced 28.3% mean weight loss at 80 weeks, with 45.3% of patients reaching the 30% or greater threshold. In the extension cohort (BMI of 35 or above), the mean reached 30.3% at 104 weeks.
Scientific American’s Daniel Drucker (University of Toronto) said: “If it’s approved, this would be the drug that people who need to lose the most amount of weight would gravitate to.” The positioning is clear: retatrutide will be the pharmacological alternative to surgery for patients with the most severe obesity.
Safety Profile
Safety was consistent with the incretin drug class. Approximately one-third of participants reported nausea or diarrhea. Approximately one-quarter reported constipation. Vomiting ranged from 10% to 25% depending on dose. The gastrointestinal side effects are similar in type to what is observed with Zepbound and Wegovy but occurred at somewhat higher rates with the higher retatrutide doses, which is expected given the more potent metabolic effect.
Notably, the 4 mg dose showed a lower adverse event discontinuation rate than placebo, suggesting that patients who start at the lowest dose and titrate up may tolerate the drug well. The titration strategy—starting low and increasing dose over time—has been the standard approach for all GLP-1 class drugs and appears to be equally important for the triple agonist. Patients who tolerate the 4 mg dose can progressively increase to 9 mg or 12 mg based on their weight-loss goals and tolerability.
The safety profile will be a key element of the retatrutide prescribing narrative. For patients considering bariatric surgery, the comparison is not just about weight-loss magnitude—it is also about risk. Surgery carries operative complications, anesthesia risk, and long-term nutritional consequences. Retatrutide carries gastrointestinal side effects that are manageable through dose titration. For many patients, the risk-benefit calculus will clearly favor the pharmacological approach.
The Commercial Projections
Truist analysts wrote: “We believe these data set a new benchmark for anti-obesity medications and will support retatrutide approval and use in patients that are not adequately served with existing incretin options.” The firm projected conservative worldwide peak sales of $12 billion to $19 billion. GlobalData forecasts $15.6 billion in 2031 sales. BMO anticipates a 2027 launch.
Those projections position retatrutide as potentially one of the largest pharmaceutical product launches in history. Retatrutide would not replace Zepbound or Foundayo—it would serve a different patient population requiring maximum weight loss while those drugs continue serving patients with less severe obesity who prioritize convenience (Foundayo) or established injectable efficacy (Zepbound).
Our Pro brief analyzes how 28.3% weight loss repositions the entire competitive landscape, breaks down Lilly’s emerging three-tier obesity strategy across Foundayo, Zepbound, and retatrutide, and assesses why Truist’s peak sales estimate may be conservative. [Details below.]
What to Watch
Seven more TRIUMPH Phase 3 readouts are expected in 2026. The most important are TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease). The type 2 diabetes trial is significant because it would support a T2D label for retatrutide, expanding the addressable market beyond obesity to the 37 million Americans with diabetes. The cardiovascular disease trial is potentially the most commercially consequential: if retatrutide demonstrates cardiovascular risk reduction—similar to what injectable Wegovy showed in the SELECT trial—the drug would have both the weight-loss efficacy and the CV safety data to support the broadest possible label and the strongest formulary positioning.
Additional TRIUMPH trials are evaluating retatrutide in obstructive sleep apnea, chronic low back pain, and metabolic dysfunction-associated steatotic liver disease. Each of these obesity-related conditions represents a distinct commercial opportunity where maximum weight loss could produce the greatest clinical benefit.
BMO’s anticipated 2027 launch implies an NDA filing in late 2026 or early 2027. Watch for Lilly’s filing timeline announcement, potentially at the December 7 Investment Community Meeting.
Lilly Acquires Engage Biologics in Its Seventh Deal of 2026
What Happened: Lilly acquired Engage Biologics, a California-based preclinical biotech developing non-viral DNA delivery systems. Financial terms were not disclosed. This is Lilly’s seventh deal of 2026.
Why Non-Viral Delivery Matters Now
Engage’s non-viral DNA delivery platform complements Lilly’s growing gene therapy portfolio by adding a delivery approach that avoids viral vectors entirely. Lilly’s existing gene therapy investments span Kelonia (lentiviral in vivo CAR-T), Orna (circular RNA in vivo CAR-T), and Profluent (AI-designed recombinases). Each uses a different delivery mechanism.
The timing is notable. This week’s STAT report linking a boy’s brain tumor to an AAV viral delivery system used in gene therapy has heightened safety scrutiny on viral vector approaches. A non-viral delivery platform that can achieve therapeutic gene transfer without the theoretical cancer risk of viral integration would address the most significant safety concern facing the gene therapy field. Engage’s technology is preclinical, meaning it is years from clinical application, but the strategic logic of acquiring non-viral delivery capability at this moment is clear.
Lilly’s 2026 deal count now stands at seven: Orna ($2.4 billion), Centessa ($7.8 billion), Kelonia (up to $7 billion), CrossBridge (up to $300 million), Ajax (up to $2.3 billion), Profluent ($2.25 billion collaboration), and now Engage (undisclosed).
BioMarin’s Voxzogo Hits Phase 3 in Hypochondroplasia
What Happened: BioMarin reported that Voxzogo (vosoritide) met the primary endpoint in a pivotal Phase 3 study in children with hypochondroplasia, a rare skeletal condition causing short stature that is related to but milder than achondroplasia. The Pharma Letter said the data could “potentially open the way for the first approved treatment for the condition.”
Why This Matters: Voxzogo is already approved for achondroplasia and has become a significant revenue driver for BioMarin. The hypochondroplasia label expansion would extend the drug’s franchise into a closely related rare disease with no current approved treatment, broadening the addressable patient population while leveraging the existing commercial infrastructure and physician relationships that BioMarin has built around the achondroplasia indication. This is also a welcome positive readout for BioMarin following its Phase 3 failure in another rare disease program reported earlier this week.
FDA Grants Kerendia Priority Review for Type 1 Diabetes with CKD
The FDA accepted Bayer’s supplemental NDA and granted Priority Review for Kerendia (finerenone) for adults with type 1 diabetes and chronic kidney disease. Kerendia is currently approved for CKD associated with type 2 diabetes. Expanding to type 1 diabetes would add a patient population with significant unmet need for kidney-protective therapies—type 1 diabetes patients develop CKD at high rates but have had limited access to therapies specifically studied in their population. The Priority Review designation reflects the FDA’s recognition of this unmet need and shortens the expected review timeline. Kerendia works through a different mechanism than the SGLT2 inhibitors that have become standard of care for diabetic kidney disease, acting as a non-steroidal mineralocorticoid receptor antagonist that reduces fibrosis and inflammation in the kidney. A T1D label expansion would strengthen Bayer’s cardiorenal franchise at a time when the company is rebuilding its pharma pipeline after the Perfuse ophthalmology acquisition earlier this month.
Strategic Themes
1. 28.3% Weight Loss Redefines What Pharmacological Obesity Treatment Can Achieve
Before retatrutide, the ceiling for drug-induced weight loss was approximately 22% (Zepbound). Retatrutide moves that ceiling to 28.3% at 80 weeks and 30.3% at 104 weeks in the most severely obese patients. The 30% threshold is particularly significant because it has historically required surgery to achieve. A once-weekly injection that delivers surgical-level weight loss without the procedural risk, recovery time, anatomical changes, and lifelong dietary restrictions of bariatric surgery represents a fundamental shift in how severe obesity will be treated. Patients who would previously have been told that only surgery could produce the weight loss they need now have a pharmacological option that approaches the same outcome through a weekly injection.
2. Lilly Is Building the Broadest Obesity Franchise in Pharmaceutical History
Foundayo for oral convenience. Zepbound for injectable efficacy. And now retatrutide for maximum weight loss approaching surgical levels. No other company has three distinct obesity products spanning the full severity spectrum from moderate overweight to the most severe obesity. Novo has Wegovy (injectable) and oral Wegovy (pill), but both use the same molecule and deliver similar weight loss. Lilly’s three products use different mechanisms (oral GLP-1, injectable GIP/GLP-1, injectable GIP/GLP-1/glucagon), target different patient populations, and deliver clinically distinct outcomes. The portfolio breadth creates a competitive moat that no single product from any competitor can match.
3. The TRIUMPH Program Has Seven More Readouts This Year
TRIUMPH-1 is the first of eight planned Phase 3 trials. TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) are the most commercially significant. Additional trials are evaluating retatrutide in obstructive sleep apnea, chronic low back pain, and metabolic dysfunction-associated steatotic liver disease. Each positive readout expands the label, the addressable population, and the commercial opportunity. If the cardiovascular trial shows risk reduction comparable to Wegovy’s SELECT data, retatrutide would have both the weight-loss efficacy and the cardiovascular safety data to support the broadest possible label.
4. The $12B to $19B Peak Sales Projection May Understate the Opportunity
Truist’s projection assumes retatrutide serves the severe obesity population that existing drugs do not adequately address. But the 104-week extension data—30.3% weight loss, with patients still losing weight at two years—suggest the drug could also attract patients currently considering bariatric surgery, patients who have plateaued on Zepbound or Wegovy, and patients with obesity-related comorbidities (sleep apnea, liver disease, cardiovascular disease) where maximum weight loss produces the greatest clinical benefit. If retatrutide captures even a fraction of the bariatric surgery market alongside its pharmaceutical market share, the peak sales ceiling may be higher than current projections reflect.
Frequently Asked Questions
What is retatrutide?
A first-in-class once-weekly injectable GIP/GLP-1/glucagon triple hormone receptor agonist developed by Eli Lilly. It targets three metabolic pathways simultaneously, producing more weight loss than any drug tested in a Phase 3 trial.
How much weight did patients lose?
At the 12 mg dose: 70.3 pounds (28.3%) over 80 weeks. In the extension cohort (BMI of 35 or above): 85.0 pounds (30.3%) at 104 weeks. 45.3% achieved 30% or greater weight loss.
How does retatrutide compare to existing obesity drugs?
Retatrutide at 28.3% exceeds Zepbound (approximately 22%), Wegovy (approximately 15%), and Foundayo (approximately 12%). The triple receptor mechanism—adding glucagon to GIP and GLP-1—appears to drive the additional weight loss through increased energy expenditure and fat oxidation.
What are the peak sales projections?
Truist projected conservative worldwide peak sales of $12 billion to $19 billion. GlobalData forecasts $15.6 billion by 2031. BMO anticipates a 2027 launch.
What are the side effects?
Consistent with the incretin class: approximately one-third experienced nausea or diarrhea, approximately one-quarter experienced constipation, and vomiting ranged from 10% to 25% depending on dose. The 4 mg dose showed a lower adverse event discontinuation rate than placebo.
How many more TRIUMPH readouts are expected?
Seven more in 2026, including TRIUMPH-2 (type 2 diabetes), TRIUMPH-3 (established cardiovascular disease), and trials in sleep apnea, chronic low back pain, and liver disease.
What is the Engage Biologics acquisition?
Lilly’s seventh deal of 2026. Engage develops non-viral DNA delivery systems, complementing Lilly’s gene therapy portfolio (Kelonia, Orna, Profluent) by adding a delivery approach that avoids the viral vectors associated with recent safety concerns.
What was the BioMarin Voxzogo result?
Voxzogo met its primary endpoint in a pivotal Phase 3 study in children with hypochondroplasia, potentially opening the path to the first approved treatment for the condition and extending the drug’s existing achondroplasia franchise.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Retatrutide vs. Everything. We compile the complete competitive comparison across retatrutide, Zepbound, Wegovy, Foundayo, oral Wegovy, and the broader obesity pipeline—mechanism, weight loss, duration, pricing, and clinical positioning—into a single framework that defines the obesity market hierarchy heading into 2027.
Lilly’s Three-Tier Obesity Strategy. We analyze how Foundayo (oral convenience), Zepbound (injectable standard), and retatrutide (maximum efficacy) create a portfolio that covers the full obesity severity spectrum, assess how Lilly will sequence and price three products from the same company, and model the total franchise revenue potential.
The $12B to $19B Question. We assess why Truist’s peak sales estimate may be conservative, model the bariatric surgery displacement opportunity, and evaluate how the TRIUMPH-2 and TRIUMPH-3 readouts could expand the commercial case into cardiometabolic disease prevention.
Plus: Engage Biologics non-viral delivery analysis, BioMarin Voxzogo hypochondroplasia franchise extension, Kerendia T1D CKD expansion, ASCO 9-day countdown, and the updated catalyst calendar through 2027.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
